15th Annual eyeforpharma Barcelona 2017

14 - 16 March 2017, Barcelona, Spain.
eyeforpharma Barcelona is Europe's largest commercial pharma meeting of 1000+ industry leaders focused on commercial innovation, engagement strategy, patient centricity and stakeholder collaboration.

1000+ delegates, 80+ senior level speakers, 6 key themes - find out more here.

Speakers include:

  • Richard Francis, CEO, Sandoz
  • Esteban Plata, President International, Western Europe & Canada, AbbVie
  • Greg Behar, CEO, Nestlé Health Science
  • Gitte Aabo, CEO, LEO Pharma
  • Brian Otis, CTO, Verily (Google Life Sciences)

Why Barcelona?

  • Collaborative setting: Our aim is to ensure your key stakeholders are present to advance partnerships with healthcare, technology, patients and patient associations
  • An inspiring agenda: As you undergo a commercial evolution we will cover 6 key themes, provide intimate workshops and keynote sessions to help direct your journey
  • 1000+ in attendance: If you are looking for one commercial meeting to attend in 2017, Barcelona will be sure to give you the most senior networking opportunities possible

World Pharma News readers can benefit from an exclusive discount - save €200 using our unique discount code WPN200 when you register online.

For more information and to reserve your pass, visit the Barcelona website.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry’s health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...

Soy lecithin NSAID combo drug protects against can…

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSA...